Molecular and Cellular Biochemistry

, Volume 289, Issue 1–2, pp 55–63 | Cite as

The Effect of Euryale Ferox (Makhana), an Herb of Aquatic Origin, on Myocardial Ischemic Reperfusion Injury

  • Samarjit Das
  • Peter Der
  • Utpal Raychaudhuri
  • Nilanjana Maulik
  • Dipak K. DasEmail author


Fox nut or gorgon nut (Euryale ferox – Family Nymphaeaceae), popularly known as Makhana, has been widely used in traditional oriental medicine to cure a variety of diseases including kidney problems, chronic diarrhea, excessive leucorrhea and hypofunction of the spleen. Based on the recent studies revealing antioxidant activities of Euryale ferox and its glucosides composition, we sought to determine if Euryale ferox seeds (Makhana) could reduce myocardial ischemic reperfusion injury. Two different models were used: acute model, where isolated rat hearts were preperfused for 15 min with Krebs Henseleit bicarbonate (KHB) buffer containing three different doses of makhana (25, 125 or 250 μg/ml) followed by 30 min of ischemia and 2 h of reperfusion; and chronic model, where rats were given two different doses of makhana (250 and 500 mg/kg/day) for 21 days, after which isolated hearts were subjected to 30 min of ischemia followed by 2 h of reperfusion. In both cases, the hearts of the Makhana treated rats were resistant to ischemic reperfusion injury as evidenced by their improved post-ischemic ventricular function and reduced myocardial infarct size. Antibody array technique was used to identify the cardioprotective proteins. The Makhana-treated hearts had increased amounts of thioredoxin-1 (Trx–1) and thioredoxin-related protein-32 (TRP32) compared to the control hearts. Western blot analysis confirmed increased expression of TRP32 and thioredoxin proteins. In vitro studies revealed that Makhana extracts had potent reactive oxygen species scavenging activities. Taken together, the results of this study demonstrate cardioprotective properties of Makhana and suggest that such cardioprotective properties may be linked with the ability of makhana to induce TRP32 and Trx-1 proteins and to scavenge ROS.


Euryale ferox gorgon nuts makhana antioxidant reactive oxygen species cardioprotection ischemia/reperfusion injury thioredoxin 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    McGuffin M, Hobbs C, Upton R (eds): American products association's botanical safety handbook. Boca Raton, FL: CRC Press, 1997, pp51Google Scholar
  2. 2.
    Lee SE, Ju EM, Kim JH: Antioxidant activity of extracts from Euryale ferox seed. Exp Mol Med 34: 100–106, 2002PubMedGoogle Scholar
  3. 3.
    Zhao H, Zhao S, Sun C, Guillaume D: Glucosylsterols in extracts of Euryale ferox identified by high resolution NMR and mass spectroscopy. J Lipid res 30: 1633–1637, 1989PubMedGoogle Scholar
  4. 4.
    Normen L, Shaw CA, Fink CS, Awad AB: Combination of phytosterols and omega-3 fatty acids: A potential strategy to promote cardiovascular health. Current Med Cardiovasc Hematological Agents 2: 1–12, 2004CrossRefGoogle Scholar
  5. 5.
    Das DK, Maulik N: Antioxidant effectiveness in ischemia-reperfusion tissue injury. Methods in Enzymology 233: 601–610, 1994PubMedCrossRefGoogle Scholar
  6. 6.
    Engelman DT, Watanabe M, Engelman RM, Rousou JA, Kisin E, Kagan VE, Maulik N, Das DK: Hypoxic preconditioning preserves antioxidant reserve in the working rat heart. Cardiovasc Res 29: 133–140, 1995PubMedCrossRefGoogle Scholar
  7. 7.
    Hattori R, Otani H, Maulik N, Das DK: Pharmacological preconditioning with resveratrol: Role of nitric oxide. Am J Physiol Heart Circ Physiol. 282: H1988–H1995, 2002PubMedGoogle Scholar
  8. 8.
    Ray PS, Maulik G, Cordis GA, Bertelli AA, Bertelli A, Das DK: The red wine antioxidant resveratrol protects isolated rat hearts from ischemia reperfusion injury. Free Radic Biol Med 27: 160–169, 1999PubMedCrossRefGoogle Scholar
  9. 9.
    Mathur P, Kaga S, Zhan L, Das DK, Maulik N: Antibody array technique reveals overexpression of important DNA-repair proteins during cardiac ischemic preconditioning. J Mol Cell Cardiol 38: 99–102, 2005PubMedCrossRefGoogle Scholar
  10. 10.
    Mathur P, Kaga S, Zhan L, Das DK, Maulik N: Potential candidates for ischemic preconditioning-associated vascular growth pathways revealed by antibody array. Am J Physiol 288: H3006–H3010, 2005Google Scholar
  11. 11.
    Sato M, Cordis GA, Maulik N, Das DK: SAPKs regulation of ischemic preconditioning. Am J Physiol Heart Circ Physiol 279: H901–H907, 2000PubMedGoogle Scholar
  12. 12.
    Maulik G, Maulik N, Bhandari V, Kagan VE, Pakrashi S, Das DK: Evaluation antioxidant effectiveness of a few herbal plants. Free Rad Res 27: 221–228, 1997CrossRefGoogle Scholar
  13. 13.
    Das DK, Engelman RM, Rousou JA, Breyer RH, Otani H, Lemeshow S: Pathophysiology of superoxide radical as potential mediator of reperfusion injury in pig heart. Basic Res Cardiol 81:155–166, 1986PubMedCrossRefGoogle Scholar
  14. 14.
    Das DK, Cordis GA: High performance liquid chromatographic detection of hydroxylated benzoic acids as indirect measure of hydroxyl radical in heart: Its possible link with the myocardial reperfusion injury. J Chromatogr 536: 273–282, 1991PubMedCrossRefGoogle Scholar
  15. 15.
    Arner ESJ, Holmgren A: Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem 267: 6102–6109, 2000PubMedCrossRefGoogle Scholar
  16. 16.
    Nakamura H, Vaage J, Valen G, Padilla CA, Bjornstedt M, Holmgren A: Measurements of plasma glutaredoxin and thioredoxin in healthy volunteers and during open-heart surgery. Free Rad Biol Med 24: 1176–1186, 1998PubMedCrossRefGoogle Scholar
  17. 17.
    Turoczi T, Chang VW, Engelman RM, Maulik N, Ho YS, Das DK: Thioredoxin redox signaling in the ischemic heart: An insight with transgenic mice overexpressing Trx1. J Mol Cell Cardiol Lee KK, Murakawa M, Takahashi S Tsubuki S, 35: 695–704, 2003CrossRefGoogle Scholar
  18. 18.
    Kawashima S, Sakamaki K, Yonehara S: Purification, molecular cloning, and characterization of TRP32, a novel thioredoxin-related mammalian protein of 32 kDa. J Biol Chem 273: 19160–19166, 1998PubMedCrossRefGoogle Scholar
  19. 19.
    Myrset AH, Bostad A, Jamin N, Lirsac PN, Toma F, Gabrielsen OS: DNA and redox state induced conformational changes in the DNA-binding domain of the Myb oncoprotein. EMBO J 12: 4625–4633, 1993PubMedGoogle Scholar
  20. 20.
    Matthews JR, Wakasugi N, Virelizier JL, Yodoi J, Hay RT: Thioredoxin regulates the DNA binding activity of NFkB by reduction of a disulphide bond involving cysteine 62. Nucleic Acids Res 20: 3821–3839, 1992PubMedCrossRefGoogle Scholar
  21. 21.
    Maulik N, Sato M, Price BD, Das DK: An essential role of NFkB in tyrosine kinase signaling of p38MAPK regulation of myocardial adaptation to ischemia. Febs Lett 429: 365–369, 1998PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  • Samarjit Das
    • 1
  • Peter Der
    • 1
  • Utpal Raychaudhuri
    • 2
  • Nilanjana Maulik
    • 1
  • Dipak K. Das
    • 1
    • 3
    Email author
  1. 1.Cardiovascular Research CenterUniversity of Connecticut School of MedicineFarmingtonUSA
  2. 2.Department of Food Technology & Biochemical EngineeringJadavpur UniversityKolkataIndia
  3. 3.Professor & Director, Cardiovascular Research CenterUniversity of Connecticut School of MedicineFarmingtonUSA

Personalised recommendations